Allogeneic hematopoietic stem cell transplantation in pediatric chronic myelogenous leukemia cases: Hacettepe experience.
Recently, there are emerging reports on the beneficial effect of imatinib mesylate for pediatric CML patients; however, the general recommendation is that high-risk CML patients with a human leukocyte antigen-identical donor should be transplanted within the first 12 months after diagnosis. Herein, the data of 16 allogeneic HSCT in 14 children with CML were analyzed retrospectively. In the present study, three-yr EFS was 54.1+/-10.8% and three-yr OS was found as 80.7+/-12.5%.
Unal
Sule
S
Division of Pediatric Hematology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Sihhiye, Ankara, Turkey. suleunal2003@hotmail.com
Fidan
Gulin
G
Tavil
Betul
B
Cetin
Mualla
M
Cetinkaya
Duygu Uçkan
DU
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery*; D008297:Male; D012189:Retrospective Studies